Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system
Abstract
Introduction. Chondroitin sulfate (CS) and glucosamine sulfate (GS), widely used as chondroprotectors, can maintain the normal functioning of the urinary system but their effect has not been analyzed systematically.
Aim: to perform a systematic analysis of the possibilities of using CS and GS in patients with pathology of the kidneys and urinary system.
Materials and methods. Predictive analysis of 2,093 publications on the interactions of CS/GS with the functioning of the kidneys and other organs of the urinary system found at the request “(urinary OR bladder OR kidney) AND (glucosamine OR chondroitin)” by methods of the theory of topological data analysis.
Results. Disorders of cholesterol and glucosamine metabolism are characteristic of cystitis, glomerular nephritis, urinary tract infections (UTIs), urolithiasis, proteinuria, and formation of diabetic nephropathy. In addition to inhibiting the pro-inflammatory cascade NF-kB, CS/GS contribute to eliminating the deficiency of glycosaminoglycans in the pathology of urothelium, inhibit urolithiasis, inhibit the synthesis of pro-inflammatory nitric oxide NO in macrophages, and modulate O-glycosylation processes.
Conclusion. The results of fundamental and clinical studies show that subsidies of CS/GS substances of pharmacological quality per os and CS instillation in the bladder (in particular, in combination with hyaluronic acid) are the means of choice for patients suffering from osteoarthritis and diseases of the urinary system. Highly purified pharmacological CS substances are part of the preparation Chondroguard.
About the Authors
I. Yu. Torshin
Federal Research Center “Informatics and Management of the Russian Academy of Sciences”;
Moscow State University
Russian Federation
Russian Federation
Ivan Yu. Torshin – MD, PhD, Senior Researcher;
Scopus Author ID: 7003300274; RISIN SPIN-code: 1375-1114; Author ID: 54104; WOS ID: C-7683-2018.
4-2 Vavilova Str., Moscow 119333;
1 Leninskie gory, Moscow 119991
A. М. Lila
V.A. Nasonovа Research Institute of Rheumatology
Russian Federation
Russian Federation
Aleksandr M. Lila – MD, Dr Sci Med, Professor, Director
Scopus Autor ID: 6602550827; eLIBRARY ID: 367966; Researcher ID: W-3334-2017-7287-8555.
34A Kashirskoye Shosse, Moscow 115522
O. A. Limanova
Moscow State University;
Ivanovo State Medical Academy
Russian Federation
Russian Federation
Olga A. Limanova – MD, PhD, Associate Professor of the Department of Pharmacology
1 Leninskie gory, Moscow 119991;
8 Sheremetevsky prospekt, Ivanovo 153012
O. A. Gromova
Federal Research Center “Informatics and Management of the Russian Academy of Sciences”;
Moscow State University
Russian Federation
Russian Federation
Olga A. Gromova – MD, Dr Sci Med, Professor, Senior Researcher, Scientific Director; Leading Researcher, Center for Big Data Analysis
RISIN SPIN-code: 6317-9833; Author ID: 94901; Scopus Author ID: 7003589812; WOS ID: J-4946-2017
4-2 Vavilova Str., Moscow 119333;
1 Leninskie gory, Moscow 119991
References
1. Raksasuk S., Ungprasert P. Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies. Int Urol Nephrol. 2019 Dec 9. DOI: https://doi.org/10.1007/s11255-019-02346-4. PMID: 31820358.
2. Kutsenko S.A. The basics of toxicology. SPb. 2004 (In Russ).
3. Avtsyn A.P., Zhavoronkov A.A., Rish M.A., Strochkova L.S. Human microelementoses: etiology, classification, organopathology. Moscow. 1991; 496 s. (In Russ).
4. Kuklin P.P. The basics of toxicology. Textbook for universities. Moscow. 2008. (In Russ).
5. Bernetti A., Mangone M., Villani C., Alviti F., Valeo M., Grassi M.C., Migliore A., Viora U., Adriani E., Quirino N., Fioravanti A., Paoloni M. Appropriateness of clinical criteria for the use of symptomatic slowacting drug for osteoarthritis (SYSADOA). A delphi method consensus initiative among experts in Italy. Eur J Phys Rehabil Med. 2019 Oct; 55 (5): 658–664. DOI: https://doi.org/10.23736/S1973-9087.19.05633-8.
6. Gromova O.A., Torshin I.Yu., Lila A.M. et al. Chemoreactom analysis of antithrombotic effects of glucosamine sulfate and nonsteroidal anti-inflammatory drugs. Sovremennaya revmatologiya. 2019; 13 (1): 129–134 (In Russ).
7. Torshin I.Yu., Gromova O.A., Lila A.M., Naumov A.V., Sorokina M.A., Rudakov K.V. The results of a post-genomic analysis of the glucosamine sulfate molecule indicate prospects for the treatment of comorbid diseases. Sovremennaya revmatologiya. 2018; 12 (4): 129–136 (In Russ).
8. Gromova O.A., Torshin I.Yu., Lila A.M., Gromov A.N. Molecular mechanisms of glucosamine sulfate in the treatment of degenerative diseases of the joints and spine: results of proteomic analysis. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2018; 10 (2): 38–44 (In Russ).
9. Gromova O.A., Torshin I.Yu., Lila A.M., Shostak N.A., Rudakov K.V. Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2019; 11 (1): 117–124 (In Russ).
10. Bruyere O., Honvo G., Veronese N., Arden N.K., Branco J., Curtis E.M., Al-Daghri N.M., Herrero-Beaumont G. , Martel-Pelletier J., Pelletier J.-P., Rannou F., Rizzoli R., Roth R., Uebelhart D., Cooper C., Reginster J.-Y. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis & Rheumatism. December 2019; 49 (3): 337–350. DOI: https://doi. org/10.1016/j.semarthrit.2019.04.008.
11. Lila A.M., Gromova O.A. Torshin I.Yu., Nazarenko A.G., Gogolev A.Yu. Molecular effects of chondrogard in osteoarthritis and herniated discs. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2017; 9 (3): 88–97. DOI: http://dx.doi.org/10.14412/2074-2711-2017-3-88-97 (in Russ).
12. Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of recognition and classification problems. part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016; 26 (2): 274.
13. Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. part 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016; 26 (3): 483–496.
14. Torshin I.Yu. Optimal Dictionaries output information based on the criterion of Solvability and their applications in Bioinformatics. Pattern recognition and image analysis. 2013; 23 (2): 319–327.
15. Torshin I.Yu., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017; 27 (2): 184–199.
16. Zitnik M., Sosivc R., Maheshwari S., Leskovec J. BioSNAP Datasets: Stanford Biomedical Network Dataset Collection, Aug 2018. [Electronic resource] URL: http://snap.stanford.edu/biodata. Accessed: 30.01.2020.
17. The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. Jan 2019; 47 (D1): D330–D338.
18. Gromova O.A., Torshin I.Yu. Vitamin D. Paradigm shift; edited by E.I. Gusev, I.N. Zakharova. Moscow. 2017; 568 s. (in Russ).
19. De Muro P., Faedda R., Satta A., Finetti D., Masala A., Cigni A., Sanna G.M., Cherchi G.M. Urinary glycosaminoglycan composition in chronic glomerulonephritis. J Nephrol. 2005 Mar-Apr; 18 (2): 154–60. PubMed ID: 15931643.
20. Rozenberg B.B., Janssen D.A.W., Jansen C.F.J., Schalken J.A., Heesakkers J.P.F.A. Improving the barrier function of damaged cultured urothelium using chondroitin sulfate. Neurourol Urodyn. 2019 Nov 27. DOI: https://doi.org/10.1002/nau.24240. PubMed ID:31774209.
21. Bang K., Chin H.J., Chae D.W., Joo K.W., Kim Y.S., Kim S., Ju K.D., Kim H., Ahn C., Oh K.H. Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy. Yonsei Med J. 2011 Jul; 52 (4): 588–94. DOI: http://dx.doi.org/10.3349/ymj.2011.52.4.588. PubMed ID: 21623600.
22. Shebeko S.K., Zupanets I.A., Tarasenko O.O. Nephroprotective effect of N-acetylglucosamine in rats with acute kidney injury. Ceska Slov Farm. 2019 Summer; 68 (4): 173–179. PubMed ID: 31822110.
23. Meininger C.J., Kelly K.A., Li H., Haynes T.E., Wu G. Glucosamine inhibits inducible nitric oxide synthesis. Biochem Biophys Res Commun. 2000 Dec 9; 279 (1): 234–9. DOI: https://www.doi. org/10.1006/bbrc.2000.3912. PubMed ID: 11112445.
24. Mansell M.A., Jones N.F., Ziroyannis P.N., Marson W.S. N-acetylbeta-D-glucosaminidase: A new approach to the screening of hypertensive patients for renal disease. Lancet. 1978 Oct 14; 2 (8094): 803–5. DOI: https://doi.org/10.1016/S0140-6736(78)92586-2. PubMed ID:81360.
25. Joladarashi D., Salimath P.V., Chilkunda N.D. Diabetes results in structural alteration of chondroitin sulfate/dermatan sulfate in the rat kidney: effects on the binding to extracellular matrix components. Glycobiology. 2011 Jul; 21 (7): 960–72. DOI: https://doi.org/10.1093/glycob/cwr029. Epub 2011 Mar 15. PubMed ID:21406563.
26. Kolset S.O., Reinholt F.P., Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012 Dec; 60 (12): 976– 86. DOI: https://doi.org/10.1369/0022155412465073. Epub 2012 Oct 27. PubMed ID:23103723.
27. De Muro P., Fresu P., Formato M., Tonolo G., Mameli M., Maioli M., Sanna G.M., Cherchi G.M. Urinary glycosaminoglycan and proteoglycan excretion in normoalbuminuric patients with type 1 diabetes mellitus. J Nephrol. 2002 May-Jun;15 (3): 290–6. PubMed ID:12113601.
28. Williams M.E., Tuttle K.R. The next generation of diabetic nephropathy therapies: an update. Adv Chronic Kidney Dis. 2005 Apr; 12 (2): 212-22. DOI: https://doi.org/10.1053/j.ackd.2005.01.011. PubMed ID:15822057.
29. Gellai R., Hodrea J., Lenart L., Hosszu A., Koszegi S., Balogh D., Ver A., Banki N.F., Fulop N., Molnar A., Wagner L., Vannay A., Szabo A.J., Fekete A. Role of O-linked N-acetylglucosamine modification in diabetic nephropathy. Am J Physiol Renal Physiol. 2016 Dec 1; 311 (6): F1172– F1181. DOI: https://doi.org/10.1152/ajprenal.00545.2015. Epub 2016 Mar 30. PubMed ID:27029430.
30. Gromova O.A., Torshin I.Yu., Lila A.M., Naumov A.V., Rudakov K.V. O bezopasnosti primeneniya glyukozamina sul’fata u patsientov s rezistentnost’yu k insulinu. Consilium Medicum. 2019; 21 (4):22-30. DOI: 10.26442/20751753.2019.4.190309.
31. Grases F., Costa-Bauza A., March J.G., Masarova L. Glycosaminoglycans, uric acid and calcium oxalate urolithiasis. Urol Res. 1991; 19 (6): 375–80. DOI: https://doi.org/10.1007/BF00310153. PubMed ID:1759332.
32. Khan S.R., Kok D.J. Modulators of urinary stone formation. Front Biosci. 2004 May 1; 9: 1450-82. DOI: 10.2741/1347. PubMed ID:14977559.
33. Dissayabutra T., Kalpongnukul N., Chindaphan K., Srisa-Art M., Ungjaroenwathana W., Kaewwongse M., Iampenkhae K., Tosukhowong P. Urinary sulfated glycosaminoglycan insufficiency and chondroitin sulfate supplement in urolithiasis. PLoS One. 2019 Mar 7; 14 (3): e0213180. DOI: https://doi.org/10.1371/journal.pone.0213180. eCollection 2019. PubMed ID:30845174.
34. Michelacci Y.M., Glashan R.Q., Schor N. Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Kidney Int. 1989 Dec; 36 (6): 1022-8. DOI: 10.1038/ki.1989.296. PubMed ID:2601252.
35. Jo J.K., Kim J.H., Kim K.S., Chung J.H., Kim Y.T., Choi H.Y., Song E.S., Lee B., Lee S.W. Effect of highly concentrated hyaluronic acid/chondroitin sulphate instillation on ureteric stent-induced discomfort after ureteroscopic lithotripsy: a multicentre randomised controlled pilot study. BJU Int. 2018 Nov; 122 (5): 858–865. DOI: https://doi.org/10.1111/bju.14392. Epub 2018 Jun 25. PubMed ID:29772114.
36. Baggio B., Gambaro G., Marzaro G., Marchini F., Borsatti A., Crepaldi G. Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis. Eur J Clin Pharmacol. 1991; 40 (3): 237–40. DOI: https://doi.org/10.1007/BF00315202. PubMed ID:2060558.
37. Gromova O.A., Torshin I.Yu., Tetruashvili N.K. Sistematicheskii analiz issledovanii po D-mannoze i perspektivy ee primeneniya pri retsidiviruyushchikh infektsiyakh mochepolovykh putei u zhenshchin reproduktivnogo vozrasta. Akusherstvo, ginekologiya i reproduktsiya /Obstetrics, gynecology and reproduction. 2019; 13 (2): 119–131. DOI: https://doi.org/10.17749/2313-7347.2019.13.2.119-131.
38. Vaisanen-Rhen V., Korhonen T.K., Finne J. Novel cell-binding activity specific for N-acetyl-D-glucosamine in an Escherichia coli strain. FEBS Lett. 1983 Aug 8; 159 (1–2): 233–6. DOI: https://doi. org/10.1016/0014-5793(83)80453-0. PubMed ID:6409669.
39. Schiavi M.C., Porpora M.G., Vena F., Prata G., Sciuga V., D’Oria O., Di Tucci C., Savone D., Aleksa N., Giannini A., Nusiner M.P., Zullo M.A., Muzii L., Benedetti Panici P. Orally Administered Combination of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin in the Prevention of Postcoital Recurrent Urinary Tract Infections: Analysis of 98 Women in Reproductive Age After 6 Months of Treatment. Female Pelvic Med Reconstr Surg. 2019 Jul/Aug; 25 (4): 309–312. DOI: https://doi.org/10.1097/SPV.0000000000000560. PubMed ID:29389678.
40. Goddard J.C., Janssen D.A.W. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018 Jul; 29 (7): 933-942. DOI: https://doi.org/10.1007/s00192-017-3508-z. Epub 2017 Nov 27. PubMed ID:29181550.
41. Panchaphanpong J., Asawakarn T., Pusoonthornthum R. Effects of oral administration of N-acetyl-d-glucosamine on plasma and urine concentrations of glycosaminoglycans in cats with idiopathic cystitis. Am J Vet Res. 2011 Jun; 72 (6): 843-50. DOI: https://doi.org/10.2460/ajvr.72.6.843. PubMed ID:21627533.
42. Hurst R.E., Roy J.B., Min K.W., Veltri R.W., Marley G., Patton K., Shackelford D.L., Stein P., Parsons C.L. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996 Nov; 48 (5): 817–21. DOI: https://doi.org/10.1016/S0090-4295(96)00322-6. PubMed ID:8911536.
43. Stellavato A., Pirozzi A.V.A., Diana P., Reale S., Vassallo V., Fusco A., Donnarumma G., De Rosa M., Schiraldi C. Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation. PLoS One. 2019 Jun 25; 14 (6): e0218475. DOI: https://doi.org/10.1371/journal.pone.0218475. eCollection 2019. PubMed ID:31237905.
44. Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015 Dec; 4 (6): 638–42. DOI: https://doi.org/10.3978/j.issn.2223-4683.2015.11.04. PubMed ID:26816865.
45. Wyndaele J.J.J., Riedl C., Taneja R., Lovasz S., Ueda T., Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019 Feb; 38 (2): 535-544. DOI: https://doi.org/10.1002/nau.23900. Epub 2018 Dec 28. PubMed ID:30592544.
46. Imperatore V., Creta M., Di Meo S., Buonopane R., Longo N., Fusco F., Spirito L., Imbimbo C., Mirone V. Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: Preliminary experience with one-year follow-up. Arch Ital Urol Androl. 2018 Mar 31; 90 (1): 11–14. DOI: https://doi. org/10.4081/aiua.2018.1.11. PubMed ID:29633792.
47. Sherif H., Sebay A., Kandeel W., Othman T., Fathi A., Mohey A., Eshazly A. Safety and efficacy of Intravesical hyaluronic acid/chondroitin sulfate in the treatment of refractory painful bladder syndrome. Turk J Urol. 2018 Nov 21; 45 (4): 296–301. DOI: 10.5152/tud.2018.63600. PubMed ID:30475699.
48. Ozkidik M. Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome. Cent European J Urol. 2019; 72 (3): 270–275. DOI: 10.5173/ceju.2019.0007. Epub 2019 Sep 16. PubMed ID:31720029.
49. Wood M.W., Barrett-Wilt G.A. Effect of twice-daily oral administration of a chondroitin sulfate-containing supplement on urine chondroitin sulfate concentrations in dogs. Am J Vet Res. 2019 Aug; 80 (8): 799–805. DOI: https://doi.org/10.2460/ajvr.80.8.799. PubMed ID:31339761.
50. Aboyan I.A., Aboyan V.E., Pavlov SV, Zinkovskaya O.V., Pavlov D.S. A comparative analysis of intravesical sodium hyaluronate monotherapy and its combination with oral chondroitin sulfate in patietns with bladder pain syndrome/intersticial cystitis. Urologiia. 2019 Apr; (1): 35-39. PubMed ID:31184015.
51. Pyo J.S., Cho W.J. Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome. Cell Physiol Biochem. 2016; 39 (4): 1618–25. DOI: https://doi. org/10.1159/000447863. Epub 2016 Sep 15. PubMed ID:27627755.
52. Dudko V.V., Avdeeva E.Yu. Determination of the purity of medicines: guidelines for seminars and laboratories. Tomsk. 2011; 129 s. (in Russ).
53. State Pharmacopoeia of the Russian Federation. 14th ed. Volume 1. Scientific center for the examination of medical devices, Federal Electronic Medical Library. Moscow. 2018. (in Russ).
54. Torshin I.Yu., Gromova O.A., Toguzov R.T., Volkov A.Yu. The elemental composition of neuroprotectors of natural origin. News of medicine and pharmacy. Nevrologiya i revmatologiya. Prilozhenie k zhurnalu Consilium Medicum. 2010; 316: 23. (in Russ).
55. Gromova O.A., Torshin I.Yu., Yurgel’ I.S., Nazarenko O.A., Rudakov K.V. Mechanisms of action and clinical efficacy of the combined hepatoprotective drug Progepar. Trudnyi patsient. 2009; 7 (12): 35–38. (in Russ).
56. Gromova O.A., Torshin I.Yu., Volkov A.Yu., Smarygin S.N., Nazarenko O.A., Karimova I.M. The drug laennec: elemental composition and pharmacological action. Plasticheskaya khirurgiya i kosmetologiya. 2011; 2: 327–333. (in Russ).
For citation:
Torshin I.Yu., Lila A.М., Limanova O.A., Gromova O.A. Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(1):23-34. (In Russ.) https://doi.org/10.17749/2070-4909.2020.13.1.23-34
Views: 751
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 